Dentistry-focused business 32Co introduces Aerox sleep centers to address the growing sleep disorder predicament in the United Kingdom
32Co, a London-based healthtech company, has launched a nationwide network of sleep centres, named Aerox Sleep Centres, to treat patients with mild to moderate obstructive sleep apnoea (OSA) and problematic snoring. The first Aerox Sleep Centres will open this summer in London, Manchester, Edinburgh, and Bristol.
Filling the Gap in Sleep Disorder Treatment
The UK faces a significant challenge in treating sleep disorders, with patient access to OSA and snoring treatments limited. 32Co's Aerox Sleep Centres are designed to fill this gap by offering industry-backed treatments at local practices, making them more accessible to millions of patients.
Specialist Care for Sleep Disorders
The Aerox Sleep Centre network leverages 32Co's platform to upskill dentists in these treatments, thereby enhancing patient access to these services. The network's focus on Mandibular Advancement Devices (MADs) is supported by Professor Ama Johal, a renowned expert in dental sleep medicine, who holds a PhD in the use of these splints.
MADs are non-invasive, retainer devices used to keep airways open during sleep and offer an effective treatment against snoring. Patients will receive a full, comprehensive dental assessment, virtual review with specialists, fully customised treatment plans, and ongoing support, including collaboration with their GP.
Competitive Edge in the Market
The market for sleep disorder treatments is expanding, with various devices and treatments available. However, 32Co's localised approach and focus on dental expertise through MADs offer a competitive edge. The demand for MADs is expected to increase with the growing awareness and prevalence of sleep disorders in the UK.
32Co has raised £7 million in funding to support its expansion, including the development of the Aerox Sleep Centres. This financial backing will help strengthen its position in the UK market for MADs and sleep disorder treatments.
Collaborative Approach to Medical Knowledge
32Co's platform and clinician network facilitate world-leading clinicians to collaborate and share medical knowledge virtually. This collaborative approach ensures that patients receive the latest and most effective treatments for their sleep disorders.
In summary, the expansion of 32Co's Aerox Sleep Centres is poised to significantly impact the market for Mandibular Advancement Devices in the UK by increasing accessibility and convenience for patients seeking sleep disorder treatments. The network's focus on MADs, supported by Professor Johal's expertise, offers a promising solution for the growing sleep disorder crisis in the UK.
- Beyond their London-based initiative, 32Co's Aerox Sleep Centres aim to extend their services in healthtech, targeting sleep disorder treatments for patients in Manchester, Edinburgh, and Bristol, showcasing their commitment to nationwide service.
- The scientific research behind Mandibular Advancement Devices (MADs) is backed by Professor Ama Johal, a leading expert in dental sleep medicine, demonstrating the credibility and effectiveness of these devices in treating sleep disorders.
- As the market for sleep disorder treatments grows, 32Co's Aerox Sleep Centres differentiate themselves by focusing on MADs and fostering close collaborations with dentists to provide patients with innovative, non-invasive treatment options for chronic diseases like sleep apnoea and snoring.
- In the realm of health and wellness, 32Co's expansion strategy not only addresses physical health conditions but also strives to improve mental health by providing patients with a comprehensive treatment plan, ongoing support, and a virtual review with specialists.
- With £7 million in funding sourced, 32Co and its Aerox Sleep Centres are poised to leverage technology and finance to establish a strong presence in the UK market for sleep disorder treatments and Mandibular Advancement Devices, marking a significant step in the fight against chronic diseases and unaddressed sleep disorders.
